Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
Zoetis Inc. ZTS
$69.69 +0.85% Close, Oct 2, 2026 · NYSE · Market cap $29.22B
High qualityWeak trendInexpensive vs sectorLow risk
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- At 11.5× trailing earnings, the shares trade at the lowest P/E of the company's past five years.
- Over the past year the stock returned -52.6%, behind the S&P 500 by 67.6 percentage points.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 32%
- EPS growth (TTM, YoY)Bottom 45%
- FCF growth (TTM, YoY)Bottom 47%
- Revenue growth, 3-year CAGRBottom 38%
- Revenue growth accelerationBottom 42%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 4%
- Gross marginTop 42%
- Operating marginTop 4%
- Cash conversion (OCF / net income)Bottom 25%
- Accruals (lower is better)Bottom 22%
- Net debt / EBITDA (lower is better)Bottom 39%
- Interest coverTop 13%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 4%
- Free-cash-flow yieldTop 10%
- EBITDA / enterprise valueTop 8%
- Sales / enterprise valueTop 47%
- P/E vs own 5-year history (lower is better)Top 6%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 8%
- 6-month returnBottom 8%
- 1-year return vs S&P 500Bottom 9%
- Distance from 52-week highBottom 25%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 46%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 14%
- Upside to consensus price targetBottom 30%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 9%
- Maximum drawdown, 3 yearsTop 43%
- Beta vs S&P 500 (lower is better)Top 12%
- Net debt / EBITDA (lower is better)Bottom 39%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 2.4% | 1.4% | ↓ |
| EPS growth (YoY) | 8.3% | 4.5% | ↓ |
| Gross margin | 70.0% | 70.9% | ↑ |
| Operating margin | 37.5% | 37.0% | ↓ |
| FCF margin | 23.6% | 24.9% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 1.4% | 2.4% | ↓ | Bottom 32% |
| EPS growth (TTM, YoY) | 4.5% | 8.3% | ↓ | Bottom 45% |
| Gross margin | 70.9% | 70.0% | ↑ | Top 42% |
| Operating margin | 37.0% | 37.5% | ↓ | Top 4% |
| Net margin | 27.5% | 27.8% | ↓ | — |
| Free-cash-flow margin | 24.9% | 23.6% | ↑ | — |
| Return on invested capital | 21.6% | — | Top 4% | |
| Revenue growth, 3-year CAGR | 5.4% | — | Bottom 38% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.10×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -1.8%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +0.6 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 2.00×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 14.4×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 3.04%
- Net buyback yield (TTM)
- 12.47%
- Shareholder yield
- 15.52%
- Share count change, 1 year
- -6.2%
- Share count change, 3-year CAGR
- -3.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +1.8%
- Average 2-day reaction, last 8
- -6.4%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $87.33
- Target vs current price
- +25.3%
- Analysts with a rating
- 32
- Share rating Buy or Strong Buy
- 47%
- Consensus rating
- Hold
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +1.1% | +3.9% | -1.1% | +2.4% | — |
| May 7, 2026 | -4.4% | -21.5% | -33.2% | -28.5% | -30.7% |
| Feb 12, 2026 | +5.7% | -2.4% | -1.1% | -10.3% | -35.6% |
| Nov 4, 2025 | +4.9% | -13.8% | -17.0% | -13.8% | -13.5% |
| Aug 5, 2025 | +8.6% | -3.7% | -1.8% | +0.7% | -4.2% |
| May 6, 2025 | +5.0% | -5.2% | +2.4% | +7.7% | -7.8% |
| Feb 13, 2025 | +2.2% | -5.1% | -9.5% | -7.9% | -8.4% |
| Nov 4, 2024 | +8.2% | -3.7% | -2.8% | -2.8% | -6.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | $1.87 | $1.85 | +1.1% | $2.47B |
| May 7, 2026 | $1.53 | $1.60 | -4.4% | $2.26B |
| Feb 12, 2026 | $1.48 | $1.40 | +5.7% | $2.39B |
| Nov 4, 2025 | $1.70 | $1.62 | +4.9% | $2.40B |
| Aug 5, 2025 | $1.76 | $1.62 | +8.6% | $2.46B |
| May 6, 2025 | $1.48 | $1.41 | +5.0% | $2.22B |
| Feb 13, 2025 | $1.40 | $1.37 | +2.2% | $2.32B |
| Nov 4, 2024 | $1.58 | $1.46 | +8.2% | $2.39B |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 11.5× | 32.9× | 0th | Top 4% |
| P/E (forward) | 11.1× | — | — | — |
| EV / EBITDA | 9.5× | — | — | Top 8% |
| EV / Sales | 3.89× | — | — | Top 47% |
| Free-cash-flow yield | 8.10% | — | — | Top 10% |
| Earnings yield | 8.71% | — | — | Top 4% |
P/E over the past five years
Range 12.7× – 52.5× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- -52.6%
- Earnings per share growth (TTM)
- +4.5%
- Change in P/E multiple
- -49.4%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -1.6%
- 200-day average slope (20 days)
- -4.7%
- Distance from 50-day average
- -6.3%
- Distance from 200-day average
- -29.1%
- RSI (14)
- 37.5
- Relative volume
- 1.15×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 30.2%
- Volatility vs own 5-year history
- 70th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.39
- Correlation with S&P 500
- 0.18
- Current drawdown from 1-year high
- -52.8%
- Maximum drawdown, 3 years
- -65.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 29, 2021 | Oct 1, 2026 | -72.0% | 1193 days | Not yet recovered |
| Nov 4, 2020 | Mar 4, 2021 | -17.4% | 81 days | 39 days (Apr 29, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $29.22B
- P/E (TTM)
- 11.5
- EPS, diluted (TTM)
- $6.07
- Revenue (TTM)
- $9.52B
- Dividend yield
- 3.00%
- 52-week range
- $68.77 – $148.79
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $7.78B | $8.08B | $8.54B | $9.26B | $9.47B |
| Gross profit | $5.31B | $5.48B | $5.83B | $6.40B | $6.67B |
| Operating income | $2.80B | $2.93B | $3.07B | $3.39B | $3.60B |
| Net income | $2.04B | $2.11B | $2.34B | $2.49B | $2.67B |
| EPS (diluted) | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.39B | $2.32B | $2.22B | $2.46B | $2.40B | $2.39B | $2.26B | $2.47B |
| Net income | $682.0M | $581.0M | $631.0M | $718.0M | $721.0M | $603.0M | $601.0M | $691.0M |
| EPS (diluted) | $1.50 | $1.29 | $1.41 | $1.61 | $1.63 | $1.37 | $1.42 | $1.65 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $2.21B | $1.91B | $2.35B | $2.95B | $2.90B |
| Capital expenditure | -$477.0M | -$586.0M | -$732.0M | -$655.0M | -$621.0M |
| Free cash flow | $1.74B | $1.33B | $1.62B | $2.30B | $2.28B |
| Dividends paid | -$474.0M | -$611.0M | -$692.0M | -$786.0M | -$889.0M |
| Net share buybacks | -$743.0M | -$1.59B | -$1.09B | -$1.86B | -$3.23B |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $1.68B
- Total assets
- $15.08B
- Total liabilities
- $11.93B
- Total debt
- $9.24B
- Net debt
- $7.76B
- Shareholders’ equity
- $3.15B
As of Jun 30, 2026 (filed Aug 6, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Jul 20, 2026 | $0.53 | Sep 1, 2026 |
| Apr 20, 2026 | $0.53 | Jun 2, 2026 |
| Jan 20, 2026 | $0.53 | Mar 3, 2026 |
| Oct 31, 2025 | $0.50 | Dec 2, 2025 |
| Jul 18, 2025 | $0.50 | Sep 3, 2025 |
| Apr 21, 2025 | $0.50 | Jun 3, 2025 |
| Jan 21, 2025 | $0.50 | Mar 4, 2025 |
| Oct 31, 2024 | $0.43 | Dec 3, 2024 |
Short interest
- Shares sold short
- 17,390,071
- Days to cover
- 3.83
- Change vs previous report
- -10.5%
FINRA short interest, settlement date Sep 15, 2026.